Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

[Atypical femoral fractures in long-term osteoporotic treatment with bisphosphonates].

Thein R, Tenenbaum S, Chechick O, Hershkovitz O, Chechik A, Caspi I.

Harefuah. 2012 Sep;151(9):532-6, 555. Hebrew.

PMID:
23367748
2.

[Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].

Soen S.

Clin Calcium. 2012 Jun;22(6):919-22. doi: CliCa1206919922. Japanese.

PMID:
22653034
3.

Atypical femoral fractures and their relation to bisphosphonate use.

Tripto-Shkolnik L.

Isr Med Assoc J. 2013 Aug;15(8):447-50. Review. No abstract available.

4.

FDA advisers uneasy about long-term bisphosphonate use.

Traynor K.

Am J Health Syst Pharm. 2011 Nov 1;68(21):2006, 2008. doi: 10.2146/news110070. No abstract available.

PMID:
22011976
5.
6.

Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.

Nieves JW, Cosman F.

Curr Osteoporos Rep. 2010 Mar;8(1):34-9. doi: 10.1007/s11914-010-0007-2. Review.

PMID:
20425089
7.

Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?

McClung M.

Clin Obstet Gynecol. 2013 Dec;56(4):743-8. doi: 10.1097/GRF.0b013e3182a98295. Review.

PMID:
24177063
8.

Atypical femur fracture during bisphosphonate drug holiday: a case series.

Lovy AJ, Koehler SM, Keswani A, Joseph D, Hasija R, Ghillani R.

Osteoporos Int. 2015 Jun;26(6):1755-8. doi: 10.1007/s00198-015-3063-8. Epub 2015 Apr 2.

PMID:
25832177
9.

Disentangling the emerging evidence around atypical fractures.

Abrahamsen B, Clark EM.

Curr Rheumatol Rep. 2012 Jun;14(3):212-6. doi: 10.1007/s11926-012-0241-y. Review.

PMID:
22359230
10.

What do we know about atypical femoral fractures? Insights and enigmas.

Audran M, Cortet B, Thomas T; Bone division of the French Society for Rheumatology..

Joint Bone Spine. 2011 Dec;78(6):568-71. doi: 10.1016/j.jbspin.2011.03.015. Epub 2011 May 17. Review.

PMID:
21592839
11.

Bisphosphonates in the treatment of osteoporosis.

Diab DL, Watts NB.

Endocrinol Metab Clin North Am. 2012 Sep;41(3):487-506. doi: 10.1016/j.ecl.2012.04.007. Epub 2012 Jun 9. Review.

PMID:
22877426
12.

Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study.

Kang JS, Won YY, Kim JO, Min BW, Lee KH, Park KK, Song JH, Kim YT, Kim GH.

Int Orthop. 2014 Jun;38(6):1247-53. doi: 10.1007/s00264-013-2259-9. Epub 2014 Jan 25.

13.

Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.

Hagen JE, Miller AN, Ott SM, Gardner M, Morshed S, Jeray K, Alton TB, Ren D, Abblitt WP, Krieg JC.

J Bone Joint Surg Am. 2014 Nov 19;96(22):1905-9. doi: 10.2106/JBJS.N.00075.

PMID:
25410509
14.

Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.

Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG.

J Bone Joint Surg Br. 2012 Mar;94(3):385-90. doi: 10.1302/0301-620X.94B3.27999.

PMID:
22371548
15.

Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.

Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F.

J Clin Endocrinol Metab. 2011 Sep;96(9):2675-80. doi: 10.1210/jc.2011-0593. Epub 2011 Jul 13.

PMID:
21752890
16.

Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.

Horning JA, Czajka J, Uhl RL.

Orthopedics. 2010 Dec;33(12):902. doi: 10.3928/01477447-20101021-21. No abstract available.

PMID:
21117565
17.

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?

Pazianas M.

JAMA Intern Med. 2013 Jan 14;173(1):79-80. doi: 10.1001/2013.jamainternmed.753. No abstract available.

PMID:
23318593
18.

Bisphosphonates and atypical femoral fractures: a time for reflection.

Compston JE.

Maturitas. 2010 Jan;65(1):3-4. doi: 10.1016/j.maturitas.2009.11.002. Epub 2009 Nov 22. No abstract available.

PMID:
19932574
19.

What is the optimal duration of bisphosphonate therapy?

Ott SM.

Cleve Clin J Med. 2011 Sep;78(9):619-30. doi: 10.3949/ccjm.78a.11022. Review.

20.

Supplemental Content

Support Center